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Abstract
Around 2 million adolescents and 3 million youth are estimated to be living with HIV worldwide. Antiretroviral outcomes for
this group appear to be worse compared to adults. We report antiretroviral therapy outcomes from a rural setting in
Zimbabwe among patients aged 10–30 years who were initiated on ART between 2005 and 2008. The cohort was stratified
into four age groups: 10–15 (young adolescents) 15.1–19 years (adolescents), 19.1–24 years (young adults) and 24.1–
29.9 years (older adults). Survival analysis was used to estimate rates of deaths and loss to follow-up stratified by age group.
Endpoints were time from ART initiation to death or loss to follow-up. Follow-up of patients on continuous therapy was
censored at date of transfer, or study end (31 December 2008). Sex-adjusted Cox proportional hazards models were used to
estimate hazard ratios for different age groups. 898 patients were included in the analysis; median duration on ART was
468 days. The risk of death were highest in adults compared to young adolescents (aHR 2.25, 95%CI 1.17–4.35). Young
adults and adolescents had a 2–3 times higher risk of loss to follow-up compared to young adolescents. When estimating
the risk of attrition combining loss to follow-up and death, young adults had the highest risk (aHR 2.70, 95%CI 1.62–4.52).
This study highlights the need for adapted adherence support and service delivery models for both adolescents and young
adults.
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Background
Around 2 million adolescents and 3 million youth are estimated
to be living with HIV worldwide. Of these, 65% are young girls,
and the majority are living in sub-Saharan Africa. 41% of all new
infections in 2009 occurred in the 15–24 age group [1].
Recognising the growing need UNICEF recently released a report
highlighting the need for HIV prevention and treatment
programmes to focus specific efforts towards young people living
with HIV/AIDS [2]. Data from both Western settings [3] and
studies from resource-limited settings [4,5] suggest that antiretro-
viral treatment outcomes for young people are worse compared to
adults.
Developing a clear understanding of the outcomes, adherence
and behavioural needs of this group is essential [6–7]. Programmes
have been developed in Western settings to provide targeted
support for adolescents and youth [8], but it is unclear how
applicable these models are in resource-limited settings.
In this study, we compare retention in care in young people
receiving antiretroviral therapy in a rural setting in Zimbabwe in
order to determine which age groups are at greatest risk of adverse
outcomes in this setting.
Methods
This study was carried out in the rural district of Buhera
(population 220,000), Manicaland, where the medical aid agency
Me ´decins Sans Frontie `res (MSF) has supported the Zimbabwean
Ministry of Health and Social Welfare since the end of 2004. The
program provides ART to over 16,000 patients via 25 decen-
tralised primary health care clinics. HIV prevalence in 2009 in the
15–24 age group was 7.7% in females and 2.9% in males.
Initiation of ART during the period analysed was performed by
doctors with ongoing follow up performed by nurses according to
national guidelines during the study period. The standard first line
therapy used during the period analysed was stavudine, lamivu-
dine, and nevirapine. Eligibility criteria during the period analysed
were those patients with a CD4,200 cells/mm
3, stage 4
conditions or those with TB. Three sessions of preparatory
counselling were given prior to ART initiation followed by sessions
at weeks two, four, twelve and then three monthly during the first
year on ART. All of the decentralised primary health care sites
provided HIV and ART care to all age groups and no specialised
paediatric or adolescent services were available during the period
analysed.
The analysis was performed on data collected as part of routine
programme monitoring and evaluation. Clinicians entered clinical
information into structured clinic visit forms at each patient
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electronic patient register by dedicated data enterers. All data was
anonymized using a unique patient registration number. The
dataset included all patients aged between 10 and 30 years at the
time of ART initiation who started ART between 1
st of January
2005 and 30
th of June 2008 according to the previously stated
eligibility criteria. The cohort was stratified into four age groups in
line with international definitions [1]: 10–15 (young adolescents)
15.1–19 years (adolescents), 19.1–24 years (young adults) and
24.1–29.9 years (older adults). Loss to follow-up was defined as
non-attendance for a period of three months after the last ART
prescription had been completed. Death was defined as any death
while taking treatment. Both mortality and loss to follow up were
confirmed through family reporting and tracing performed by
support groups and a community-based NGO.
Baseline characteristics were described using median and
interquartile ranges (IQRs) for continuous variables and counts
and percentages for categorical variables. Survival analysis was
used to estimate rates of deaths and loss to follow-up stratified by
age group. Entry time into the cohort was the date of ART
initiation. Endpoints were the time from ART initiation to death
or loss to follow-up. Follow-up of patients on continuous therapy
was censored at date of transfer, or study end (31 December 2008).
Sex-adjusted Cox proportional hazards models were used to
estimate hazard ratios for different age groups. Hazard propor-
tionality was assessed by analysis of scaled Schoenfeld residuals.
Sensitivity analyses were performed to adjust for baseline immune
deficiency. Hazard ratios comparing different age groups were
estimated adjusted for baseline CD4 count (,100, 101–200,
.200) in two ways: (i) using the complete data set and (ii) creating
a separate category for missing CD4 counts. All analyses were
conducted in STATA version 11.
Table 1. Baseline Characteristics at ART Initiation.
Young adolescents Adolescents Young adults Adults Total
(10–15 years) (15.1–19 years) (19.1–24 years) (24.1–29.9 years)
(n=221) (n=85) (n=143) (n=449) (n=898)
Sex, n (%)
Female 112 (50.7) 45 (52.9) 123 (86.0) 361 (80.4) 641 (71.4)
Male 109 (49.3) 40 (47.1) 20 (14.0) 88 (19.6) 257 (28.6)
Age, median (IQR) 12.3 (11.2–13.6) 16.4 (15.6–17.7) 22.4 (21.0–23.5) 27.1 (25.9–28.2)
CD4 counts
Missing, n (%) 68 (30.8) 29 (34.1) 53 (37.1) 144 (32.1) 294 (32.7)
Available, n (%) 153 (69.2) 56 (65.9) 90 (62.9) 305 (67.9) 604 (67.3)
Medan (IQR) 154 (50–265) 102 (21–184) 111 (41–230) 111(39–224) 119 (44–236)
,100 cells/uL, n (%) 54 (35.3) 27 (48.2) 44 (48.9) 140 (45.9) 265 (43.9)
100–200 cells/uL, n (%) 36 (23.5) 18 (32.1) 14 (15.6) 65 (21.3) 133 (22.0)
.200 cells/uL, n (%) 63 (41.2) 11 (19.6) 32 (35.6) 100 (32.8) 206 (34.1)
Year of Initiation 40 (8.9) 70 (7.8)
2004–2005 (%) 20 (9.1) 5 (5.9) 5 (3.5) 73 (16.3) 156 (17.4)
2006 (%) 44 (19.9) 15 (17.7) 24 (16.8) 217 (48.3) 451 (50.2)
2007 (%) 110 (49.8) 44 (51.8) 80 (55.9) 119 (26.5) 221 (24.6)
2008 (%) 47 (21.3) 21 (24.7) 34 (23.8)
Time on ART (days),
median (IQR)
484 (334–755) 434 (259–665) 405 (216–559) 441 (240–625) 441 (257–643)
doi:10.1371/journal.pone.0052856.t001
Figure 1. Kaplan-Meier plots of deaths and loss to follow-up
stratified by age category.
doi:10.1371/journal.pone.0052856.g001
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data received approval from the Independent Ethics Review
Board of Me ´dicins Sans Frontie `res.
Results
A total of 898 patients were included in the analysis. Table 1
shows the baseline characteristics of the cohort by age group.
There was an equal proportion of males and females among the
young adolescents (49.3% male) and adolescents (47.1% male)
suggesting a higher proportion of perinatally infected children in
this group as in adult services a higher proportion of women tend
to access care; in the young adults and adult age groups the
majority of patients (.80%) were female. Median duration on
ART was 441 days (IQR 257–643), and this was highest for young
adolescents (484 days, IQR 334–755). CD4 cell counts were
missing for 294 (32.7%) patients. The proportion of missing CD4
cell counts was similar across all age categories. Median CD4 cell
count was ,200 cells/mm
3 across all age categories, and lowest
for adolescents (median CD4 102 cells/mm
3, IQR 21–184).
Overall, the rate of death was 6.2 (95%CI 4.9–7.7) per 100
person years (table 2) with the highest rates in the first months of
treatment (Figures 1 & 2). Adults had the highest rate of death at
7.7 (95%CI 5.8–10.4) per 100 person years, while young
adolescents had the lowest death rate at 3.6 (2.0–6.3) per 100
person years. In contrast, loss to follow-up was highest among the
young adults, at 16.8 (95%CI 11.6–24.3) per 100 person years,
and lowest in the young adolescent age group, at 4.2 (2.5–7.0) per
100 person years. Adjusted hazard ratios for death were highest in
adults (2.25, 95%CI 1.17–4.35) compared to young adolescents
(table 3), with no significant differences observed in the hazard of
death comparing young adolescents and adolescents or young
adults. Results were similar when adjusting for baseline immune
deficiency using a separate category for missing CD4 cell count or
restricting the analysis to the complete dataset. In contrast, young
adults and adolescents had a 2–3 times higher risk of loss to follow-
up than young adolescents (aHR 3.35, 95%CI 1.73-6.49 for young
adults and aHR 2.54, 95%CI 1.17–5.49 for adolescents). When
estimating the risk for either loss to follow-up or death young
adults had the highest risk (aHR 2.70, 95%CI 1.62–4.52). The
results remained largely unchanged when adjusting for baseline
CD4 count both when a separate category was used for missing
CD4 counts or when the analysis was restricted to the complete
dataset.
Discussion
There is growing recognition that adolescents have greater
challenges to adherence on ART compared to adults. However,
published studies from cohorts of this age group from resource-
limited settings are limited and little consistency in the age
categories used in published studies, making comparisons difficult
[4,9]. In addition the largely unrecognised epidemic of late
progressors in the young and older adolescent age groups is
evidenced by the almost equal sex distribution in these age groups
in our setting. Across Southern Africa an increasing pool of
survivors from mother-to-child transmission programmes are
entering into adolescence, with data suggesting that up to one
third of HIV infected infants, likely to have been infected during
the breast feeding period, are ‘‘slow progressors’’’’ with a median
survival of greater than ten years. In Zimbabwe, mathematical
modelling estimates that deaths among untreated slow progressors
will increase from 8000 per year in 2008 to a peak of 9700 per year
in 2014. Hence, identifying these children and addressing their
needs once on treatment is an essential challenge for antiretroviral
therapy (ART) programmes in the coming years [3].
Figure 2. Kaplan-Meier plots of loss to follow-up stratified by
age category.
doi:10.1371/journal.pone.0052856.g002
Table 2. Rates of death and Loss to follow-up.
Death Loss to follow-up
Events Person-years
Rate (95% CI) per
100 person-years Events
Person time
(years)
Rate (95% CI) per
100 person-years
Young adolescents 12 336 3.6 (2.0–6.3) 14 336 4.2 (2.5–7.0)
Adolescents 6 111 5.4 (2.4–12.1) 12 111 10.9 (6.2–19.1)
Young adults 11 166 6.6 (3.7–11.9) 28 166 16.8 (11.6–24.3)
Adults 45 582 7.7 (5.8–10.4) 45 582 7.7 (5.8–10.4)
Total 74 1200 6.2 (4.9–7.7) 99 1200 8.3 (6.8–10.1)
doi:10.1371/journal.pone.0052856.t002
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resource-limited settings, the age group with the worst outcomes
were the young adults (19.1–24 years). Cited challenges to
medication adherence in this group include side effects, appoint-
ment schedules that interfere with daily schedules, depression,
stigmatisation, fears about disease transmission, transfer to adult
HIV services [10], and disclosure of HIV status [11,12]. In this
setting partial disclosure is aimed for between the ages of seven to
nine with full disclosure completed no later than age twelve. While
no formal qualitative surveys have been done in this programme,
feedback from experienced counsellors working in these sites
suggested that context specific challenges to retention in care for
the young adult group also highlighted during informal focus
included: the transition out of education, the need to move away in
order to seek work (moving to an urban setting or moving across a
border to South Africa or Botswana); and entering into more
serious relationships and marriage where new disclosure was
needed.
Other factors that may have impacted on rates of retention rates
during the period analysed included the fact that decentralisation
to the network of primary care clinics was gradually being
implemented with patients having to travel up to 3 hours to reach
a clinic. In addition, the economic and political instability
experienced in Zimbabwe during this period may have led to
patients defaulting due to inability to pay for transport or due to
forced movement out of the district.
In a survey carried out between 1998 and 2005 in Manicaland,
Zimbabwe (the same province as this study site) the median age at
first sex and first marriage was 18.5 years and 21.4 years for men
and 18.2 years and 18.5 years for women respectively [13].
Marriage and giving birth, particularly to a first born, may be a
reason for patients to move away from their original clinic. Many
women will travel to be near a parent or in laws depending on
cultural norms and hence be lost within the ART cohort.
Various counselling and service delivery models of care have
been developed in western settings targeting adolescents. These
have also included the development of ‘‘transitioning protocols’’
from specialised adolescent clinics to the standard adult services
[8]. However, in resource-limited settings where counsellors are
often lay people with relatively low levels of education, it may not
be feasible to implement specialised counselling techniques.
Simple steps to addressing the major challenges to retention in
care should be incorporated into existing counselling tools and
service delivery models. One example being employed in one
South African adolescent project is incorporating the theme of
‘‘life steps’’ into routine counselling that aims to address the major
challenges around having to seek work and entering into new
relationships. Whether peer support for this age group is helpful is
questionable as when asked, many stated that they would prefer to
be counselled by someone older than themselves.
Adapting both provision of ART and monitoring and evalua-
tion tools to the challenge of mobility of this age group should also
be integrated into programme implementation. Counsellors and
nurses should proactively and routinely ask about travel plans for
work, education or social reasons and allow for provision of longer
drug supplies and a degree of flexibility in often rigid follow up
schedules. Being proactive in this way should allow formal
transfers out to be organised to alternative ART sites when
needed. In addition it is essential to provide a clearly documented
HIV history to the patient, the so called patient passport, enabling
the health professional at the new site to continue care in an
appropriate manner.
In addition to adapting approaches to the socioeconomic
challenges in this age group, simplification of drug delivery may
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of guidance to use a once-daily, fixed-dose combination of
tenofovir combined with lamivudine and efavirenz from the age
of twelve is expected to simplify adherence and reduce side-effects
[13]. In countries where such optimized regimens are still
unavailable for the general population due to cost concerns it
may be reasonable to consider prioritizing their use in this high
risk age group. Long acting formulations that are in development
could also be ideal to pilot for these age groups. The use of mobile
health technologies and pre-existing social network platforms may
be another attractive means of giving additional support mech-
anisms to this vulnerable age group.
As with any observational study there were several limitations to
the analysis. Incomplete baseline CD4 data did not allow for
appropriate adjustment. Adjustment for baseline CD4 count using
a separate category for missing values might have introduced bias.
This is particularly true in situations where the percentage of
missing data is high [14–17]. Restricting the analysis to records
with complete CD4 count data will also result in bias except when
the variable is missing completely at random. The proportion of
missing CD4 counts was similar across age groups and outcomes
(death and loss to follow-up). A high proportion (32.8%) of CD4
counts were missing for operational reasons, as the country was
going through a period of civil unrest with breakdown of
infrastructure. Therefore CD4 count data were likely to be
missing completely at random and analysis of the complete case
scenario can be expected to result in unbiased results. Incomplete
outcome verification for patients lost to follow up may lead to
possible misclassification of true death as loss to follow up [18].
Nevertheless, when deaths and losses were combined as a single
adverse outcome (attrition), young adults still did worse. Finally,
the fact that a proportion of adolescents may have been perinatally
infected may reflect a survival bias in this group.
In conclusion, this analysis highlights the young adult group as
being at highest risk of being lost from care compared to
adolescent and adults in a resource poor rural setting. Adapting
adherence support and service delivery models for this group
should be a priority to avoid treatment interruptions, development
of resistance and increased morbidity within this group.
Author Contributions
Conceived and designed the experiments: HB DM. Performed the
statistical analysis: KK HB. Prepared the first draft of the manuscript:
HB. Provided critical input to subsequent drafts of the manuscript: HB JM
KN NF KK DM. Approved the final version of the manuscript: HB JM
KN NF KK DM.
References
1. Anon (2011) Opportunity in crisis. Preventing HIV from adolescence to young
adulthood. UNICEF, UNAIDS, UNESCO, UNFPA, ILO, WHO and The
World Bank: New York.
2. Anon (2010) UNAIDS Report on the Global AIDS Epidemic. UNAIDS:
Geneva.
3. Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, et al (2007) Long-term
observation of adolescents initiating HAART therapy: three-year follow-up.
AIDS Res Hum Retroviruses 23: 1208–14.
4. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, et al (2009)
Antiretroviral therapy adherence, virologic and immunologic outcomes in
adolescents compared with adults in southern Africa. J Acquir Immune Defic
Syndr 51: 65–71.
5. Charles M, Noel F, Leger P, Severe P, Riviere C, et al (2008) Survival, plasma
HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian
adolescents and young adults on antiretrovirals. Bull World Health Organ 86:
970–7.
6. Ryscavage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B (2011) Clinical
outcomes of adolescents and young adults in adult HIV care. J Acquir Immune
Defic Syndr 58: 193–7.
7. Khan M, Song X, Williams K, Bright K, Sill A, et al (2009) Evaluating
adherence to medication in children and adolescents with HIV. Arch Dis Child
94: 970–3.
8. Maturo D, Powell A, Major-Wilson H, Sanchez K, De Santis JP, et al (2011)
Development of a protocol for transitioning adolescents with HIV infection to
adult care. J Pediatr Health Care 25: 16–23.
9. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, et al (2011) Survival
of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a
nationally representative cohort in Uganda. PLoS One 6: e19261.
10. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ (1999) Antiretroviral adherence
issues among HIV-positive adolescents and young adults. J Adolesc Health 25:
316–9.
11. Arrive E, Dicko F, Amghar H, Aka AE, Dior H, et al (2012) HIV Status
Disclosure and Retention in Care in HIV-Infected Adolescents on Antiretroviral
Therapy (ART) in West Africa. PLoS ONE 7: e33690.
12. Moodley K, Myer L, Michaels D, Cotton M (2006) Paediatric HIV disclosure in
South Africa – caregivers’ perspectives on discussing HIV with infected children.
S Afr Med J 96: 201–204.
13. Nachega JB, Mugavero MJ, Zeier M, Vito ´ria M, Gallant JE (2011) Treatment
simplification in HIV-infected adults as a strategy to prevent toxicity, improve
adherence, quality of life and decrease healthcare costs. Patient Prefer
Adherence 5: 357–67.
14. Cremin I, Mushati P, Hallett T, Mupambireyi Z, Nyamukapa C, et al (2009)
Measuring trends in age at first sex and age at marriage in Manicaland,
Zimbabwe. Sex Transm Infect 85 Suppl 1: i34–40.
15. Knol MJ, Janssen KJ, Donders AR, Egberts AC, Heerdink ER, et al (2010)
Unpredictable bias when using the missing indicator method or complete case
analysis for missing confounder values: an empirical example. J Clin Epidemiol
63: 728–36.
16. Demissie S, LaValley MP, Horton NJ, Glynn RJ, Cupples LA (2003) Bias due to
missing exposure data using complete-case analysis in the proportional hazards
regression model. Stat Med 22: 545–57.
17. Greenland S, Finkle WD (1995) A Critical Look at Methods for Handling
Missing Covariates in Epidemiologic Regression Analyses. American Journal of
Epidemiology 142: 1255–1264.
18. Van Cutsem G, Ford N, Hilderbrand K, Goemaere E, Mathee S (2011)
Correcting for Mortality Among Patients Lost to Follow Up on Antiretroviral
Therapy in South Africa: A Cohort Analysis. Plos One 6: e14684.
Adolescents and Youth ART Outcomes in Zimbabwe
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e52856